JPMorgan: Not overly concerned about the impact of rising interest rates on China's healthcare sector, and remains bullish on biotechnology and CXO services.

JPMorgan released a report stating that, as global interest rates—particularly the yields on 10-year and 30-year U.S. Treasuries—rise, the risk-free rate used in its DCF model and the stock valuations based on DCF are under greater pressure than before. Consequently, the firm has reassessed the potential impact of interest rates on Chinese healthcare valuations, especially within the biotechnology and CXO subsectors. If a higher risk-free rate is adopted in the DCF analysis, companies such as Insilico Medicine (03696.HK) in the AIDD space, GenScript (01548.HK) and Wuxi Apptec (02359.HK) in the CXO sector, and Junshi Biosciences (018…

AASTOCKSOct 6 10:19

VIGONVITA-B: 2026 INTERIM REPORT

HKEXSep 30 17:28

Hong Kong Stock Market Movements | Wangshan Wangshui-B (02630) rises over 4% in afternoon trading; its Class I new drug for schizophrenia, VV119, recently entered Phase II clinical trials

Wangshan Wangshui-B (02630) rose more than 4% in the afternoon. As of press time, it was up 4.63% at HK$84.7, with a turnover of HK$6.83 million.Zhitong Finance APP learned that Wangshan Wangshui-B (0

Zhitong FinanceSep 25 14:47

Wangshan Wangshui (2630.HK): Angweida Sales Ramp Up Rapidly; Psychiatric Disease Pipeline Features Distinctive Assets

EventThe company released its 2026 interim report, reporting revenue of RMB 132

China Post SecuritiesSep 11 13:29

Wangshan Wangshui-B (02630.HK): Revenue Surges as TPN171 Commercialization Momentum Fully Unleashed

In the first half of 2026, revenue posted a substantial year-over-year increase,

Sealand SecuritiesSep 10 19:11

VIGONVITA-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2026

HKEXAug 28 18:08